Moleculin Biotech Company Insiders

Moleculin Biotech Management Team Effectiveness

The company has return on total asset (ROA) of (0.6245) % which means that it has lost $0.6245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.148) %, meaning that it created substantial loss on money invested by shareholders. Moleculin Biotech's management efficiency ratios could be used to measure how well Moleculin Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.96 in 2025. Return On Capital Employed is likely to rise to -2.19 in 2025. At this time, Moleculin Biotech's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 81.9 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 11.5 M in 2025. Common Stock Shares Outstanding is likely to rise to about 3.6 M in 2025, whereas Net Loss is likely to drop (15 M) in 2025.

Moleculin Biotech Workforce Comparison

Moleculin Biotech Insider Trading

Moleculin Biotech Notable Stakeholders

The success or failure of an entity such as Moleculin Biotech often depends on how effective the management is. Moleculin Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moleculin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moleculin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Moleculin Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Moleculin Biotech. Check Moleculin Biotech's Beneish M Score to see the likelihood of Moleculin Biotech's management manipulating its earnings.

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.